Sugammadex Fresenius Kabi



This medicine is authorised for use in the European Union.


Sugammadex Fresenius Kabi is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Fresenius Kabi is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Fresenius Kabi can be used in adults who have received rocuronium and vecuronium, and in children aged 2 years or older who have received rocuronium.

Sugammadex Fresenius Kabi contains the active substance sugammadex and is a ‘generic medicine’. This means that Sugammadex Fresenius Kabi contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Bridion. For more information on generic medicines, see the question-and-answer document here.

This EPAR was last updated on 21/07/2022

Authorisation details

Product details
Sugammadex Fresenius Kabi
Agency product number
Active substance
sugammadex sodium
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Neuromuscular Blockade
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Fresenius Kabi Deutschland GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Else-Kröner-Straße 1,
61352 Bad Homburg v.d.Höhe

Product information

15/07/2022 Sugammadex Fresenius Kabi - EMEA/H/C/005760 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

All other therapeutic products

Therapeutic indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Assessment history

How useful was this page?

Add your rating
1 rating
1 rating